Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

AGTC announces data from ongoing Phase 1/2 trial 

By Brian Buntz | June 24, 2021

AGTC logoApplied Genetic Technologies Corp. (NSDQ:AGTC) has announced 12-month data from a Phase 1/2 trial involving achromatopsia, an inherited retinal condition affecting roughly 27,000 people in the U.S. and EU. Most people with achromatopsia are legally blind. 

AGTC is focusing on two gene mutations linked to the disorder known as A3 and B3. The former accounts for roughly half of the cases of achromatopsia while B3 is implicated in about one-quarter. 

The company said the ACHM B3 drug candidate shows promising signs of biologic activity based on two visual function measurements. The company acknowledged that there was presently no consistent efficacy signal of activity for ACHM A3, but that it saw encouraging patient anecdotes in the A3 cohort. 

Higher dose levels in the trials were correlated with higher response rates.

“Based on the data presented today, an important differences in our construct and clinical trial design, we are confident in our achromatopsia position and have multiple points of differentiation compared to others developing achromatopsia therapies,” said Sue Washer, CEO of AGTC in a  investor webinar. The company has conducted more preclinical research and has explored a wider dose range than other organizations developing achromatopsia drugs. 

“The results regarding responders in the ACHM B3 trial are encouraging,” said Dr. Rachel Huckfeldt, assistant professor of ophthalmology at Harvard Medical School, in a statement. 

The company believes that the A3 version of the drug may offer benefits to pediatric patients. Pediatric research involving both A3 and B3 is underway. 

AGTC plans to conduct later-stage trials focusing on the B3 drug candidate.

The company reported no serious adverse events associated with the experimental drug. 


Filed Under: clinical trials, Drug Discovery, Ophthalmology
Tagged With: A3, achromatopsia, AGTC, Applied Genetic Technologies Corp, B3
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

AMD
Promising phase 2 data suggests new drug could save sight in dry AMD
Structure of human eye. In side view.
Gene therapy yields 100x vision average improvement, with a few reaching 10,000x
Ozempic
JAMA study suggests link between semaglutide and eye disorder
Retina slice
Molecular photoswitches: Illuminating the future of inherited retinal disease treatment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE